



August 4, 2020

✓ **BSE Limited,**

Department of Corporate Services,  
P. J. Towers, Dalal Street,  
Mumbai Samachar Marg,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Ltd.,**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**MUMBAI - 400 051.**

**Dear Sir/Madam,**

**Sub: Disclosure pursuant to Regulation 30 of the SEBI  
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards receipt of tentative approval from the U.S. FDA for the Company's Empagliflozin Tablets, 10 mg and 25 mg, to market a generic version of Jardiance® Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl- : a/a.**

## Lupin Receives Tentative Approval for Empagliflozin Tablets

**Mumbai, Baltimore, August 04, 2020:** Pharma major Lupin Limited (Lupin) announced that it has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (U.S. FDA) to market a generic version of Jardiance® Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Empagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin Tablets, 10 mg and 25 mg (RLD: Jardiance®) had an annual sales of approximately USD 4,368 million in the U.S. (IQVIA MAT Mar 2020).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions and in India by global revenues. The Company invests 9.6 % of its revenues on research and development.

Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: [www.twitter.com/LupinGlobal](https://www.twitter.com/LupinGlobal) | LinkedIn: [www.linkedin.com/company/lupin/](https://www.linkedin.com/company/lupin/)

Facebook: [www.facebook.com/LupinWorld/](https://www.facebook.com/LupinWorld/)

### For further information or queries please contact –

<p><b>Arvind Bothra</b> Head – Investor Relations and Corporate Communications Email: <a href="mailto:arvindbothra@lupin.com">arvindbothra@lupin.com</a> Tel: +91 22 6640 8237</p>	<p><b>Manjira Sharma</b> General Manager – Corporate Communications Email: <a href="mailto:manjirasharma@lupin.com">manjirasharma@lupin.com</a> Tel: +91 22 6640 2532</p>
--	---

### \*Safe Harbor Statement

Jardiance® is a registered trademark of Boehringer Ingelheim International GmbH